Acute Coronary Syndrome Therapeutics Market – By Type, By Drug Class, By Route of Administration, By Age Group, By End Use – Global Forecast 2025-2034

Acute Coronary Syndrome Therapeutics Market Size

The global acute coronary syndrome therapeutics market was estimated at USD 9.4 billion in 2024. The market is expected to grow from USD 9.9 billion in 2025 to USD 17 billion in 2034, at a CAGR of 6.2%. The rising prevalence of cardiovascular diseases such as acute coronary syndrome is stimulating market demand for advanced cardiovascular drugs.
 

Acute coronary syndrome comprises conditions such as non-ST-elevation myocardial infarction (NSTEMI), ST-elevation myocardial infarction (STEMI) and unstable angina, which are the leading causes of mortality globally. According to the World Health Organization, cardiovascular diseases cause over 17.9 million deaths annually and one third of these deaths occur prematurely in people under 70 years. Moreover, according to NIH, each year more than 7 million people are diagnosed with acute coronary syndrome.
 

The increasing lifestyle related risk factors such as smoking, sedentary behavior, hypertension, and diabetes, continue to stimulate the demand for effective and rapid-response therapies. According to WHO, 31% of adults or 1.8 billion people don't meet the levels of healthy physical activity. Additionally, the increasing cases of recurrent cardiac events in aging populations are escalating investments to develop therapeutic strategies.
 

The increasing technological advancements in drug delivery systems and the innovations in next-generation cardiovascular drugs are further stimulating the competitive landscape. Innovations that include extended-release formulations and fixed-dose combinations are improving safety and efficacy. Additionally, the growing need for personalized medicine as targeted therapeutics for acute coronary syndrome helps with patient-specific profiles. Pharmaceutical companies are investing in expansion, regional manufacturing and collaborations for the rising demand across regions in both developed and undeveloped countries.
 

Moreover, the increasing need for early symptom detection and rapid diagnosis in emergency care is changing acute coronary syndrome management in developed and developing areas. In addition, government initiatives that include national heart health programs and public-private partnerships are supporting essential medical necessities. Additionally, the healthcare system is focusing on integration of pharmacological therapies such as antiplatelets, anticoagulants, thrombolytic drugs, beta-blockers, nitrates, ACE inhibitors, angiotensin II receptor blockers and statins. They are used in disease management and reduce the risk of mortality and recurrence.
 

The acute coronary syndrome therapeutics market is known to focus on the manufacturing, research and development, and distribution of drugs for treating ACS conditions. This treatment includes drugs such as antiplatelets, anticoagulants, thrombolytics, beta-blockers, calcium channel blockers, nitrates, ACE inhibitors, ARBs, statins, and other therapies. They are used for therapies in inpatient, outpatient, and emergency settings and are used to prevent myocardial damage, reduce mortality and improve cardiac health. With the increasing global cardiovascular disease, the ACS therapeutics market is increasing rapidly.
 

Acute Coronary Syndrome Therapeutics Market Trends

• The acute coronary syndrome therapeutics industry is stimulated by the rising global cases of ischemic heart conditions and secondary prevention strategies. The high number of cases of cardiovascular disease continues to rise, due to which healthcare systems are shifting from reactive emergency care to proactive medical therapy that results in risk stabilization and long-term effects. Life-threatening conditions such as myocardial infarction and unstable angina have become important for innovation in cardiology due to rising mortality cases and repeated risks.
   
• The increasing shift towards fixed-dose combination therapies is changing the treatment methods. The pharmaceutical manufacturers are combining drugs that integrate therapies such as antiplatelet agents, statins and antihypertensives in a single formulation.
   
• The increasing hospital-based acute care and community cardiac centers across geographic expansion are improving access to therapeutic solutions. Public health centers are also stimulating initiatives for the improvement of medication affordability and ensuring access to emergency cardiovascular therapeutics.
   
• The rising emergence of biologic and targeted therapies are showing high-value innovations in the market. The development of monoclonal antibodies, anti-inflammatory agents and PCSK9 inhibitors are being utilized beyond traditional oral agents. These targeted therapies are reducing plaque instability, systemic inflammation, and cholesterol levels, resulting in better outcomes for patients with high-risk conditions and those resistant to conventional treatments.
   
• Lastly, the increasing shift to real-time patient monitoring is enabling more personalized acute coronary syndrome therapeutics care. With increased use of wearable technologies, AI-assisted diagnostics and cardiac biomarker profiling, physicians are tailoring therapies to individual risk profiles. This creates new pathways for remote management of the syndrome and telecardiology services, thereby contributing to market growth.
   

Acute Coronary Syndrome Therapeutics Market Analysis

In 2021, the global market was valued at USD 8.1 billion. The following year, it saw a slight increase to USD 8.5 billion, and by 2023, the market further climbed to USD 8.9 billion.
 

Based on type, the global market is segmented into non-ST-elevation myocardial infarction (NSTEMI), ST-elevation MI (STEMI), and unstable angina. The non-ST-elevation myocardial infarction (NSTEMI) segment accounted for the highest market share and was valued at USD 6.5 billion in 2024.
 

• The increasing prevalence of non-ST-elevation myocardial infarction (NSTEMI) cases globally is stimulating the segment demand in the acute coronary syndrome therapeutics industry.
   
• NSTEMI causes most of the acute coronary cases, due to partial blockage of coronary arteries and less damage to the heart compared to STEMI, but requires urgent medical management.
   
• Moreover, the rise of lifestyle-related risk factors further contributes to the growth of NSTEMI globally. According to NIH, 70% of cases are caused by non-ST-elevation myocardial infarction (NSTEMI).
   
• Additionally, the growing advancements in diagnostics, along with sensitive troponin assays and use of cardiac imaging, have increased early detection of non-ST-elevation myocardial infarction cases. This has increased identification rates, stimulating the demand for targeted therapeutics for managing the condition and reducing progression to more severe events.
   
• Lastly, healthcare systems in both developed and developing countries are prioritizing strategies for NSTEMI patients, further increasing market growth.

Based on drug class, the global acute coronary syndrome therapeutics market is categorized into antiplatelet therapy, anticoagulants, beta blockers, nitrates, thrombolytics and other medications. The antiplatelet therapy segment dominated the market with 34.9% market share in 2024.
 

• Antiplatelet therapies are used in preventing platelet aggregation and thrombus formation, which are the primary causes of artery blockage in acute coronary syndrome. These include aspirin, clopidogrel and ticagrelor, which are used in both the acute management and long-term prevention of recurrent cardiovascular cases, making them a standard treatment option.
   
• Moreover, the broad clinical acceptance and recommendations from major cardiology associations, such as the American Heart Association and European Society of Cardiology, suggest antiplatelet agents and dual?antiplatelet therapy for high-risk patients as first-line therapy. In addition, NIH mentions the use of antiplatelet therapy for decades for acute coronary syndrome, which drives the growth of the market.
   
• Additionally, increasing innovations in antiplatelet drug development, such as faster action and improved safety, have expanded use even in high-risk and diverse populations. Pharmaceutical companies continue to invest heavily in research and commercialization of antiplatelets, further escalating the market for this drug class.
   

Based on route of administration, the global acute coronary syndrome therapeutics market is categorized into oral and injectables. The oral segment dominated the market in 2024 and is anticipated to witness growth at a CAGR of 6%.
 

• Oral medications are easy to administer compared to other routes such as parenteral, causing higher patient compliance. Adherence to oral therapies is significantly higher than for injectable treatments, as patients prefer taking a pill at home rather than visiting healthcare facilities for injections.
   
• Oral medications are more cost-effective than parenteral treatments, as they require less infrastructure for administration and fewer healthcare resources. According to WHO, oral health and therapeutics can lead to lower healthcare costs as reduction of hospital visits and specialized medical staff for administration of injections make them particularly affordable. This together spurs the market growth.
   

Based on age group, the global acute coronary syndrome therapeutics market is categorized into adults and geriatric. The geriatric age group segment dominated the market in 2024 and was valued at USD 6.5 billion in 2024.
 

• The rising cases of cardiovascular disease in the geriatric population are escalating dominance in the market. Approximately, 60-65% of cases occur in the geriatric age group. This age group is more likely to suffer from diseases and disorders such as hypertension, diabetes, and hyperlipidemia, increasing the need for clinical treatments such as antiplatelets, beta blockers, statins, and anticoagulants.
   
• Moreover, the rising geriatric population globally, in aging countries such as Japan, Germany and Italy, is expanding the market. According to the NIH, by 2030, 1 in 6 people globally will be over age 60, with the number expected to double by 2050.
   
• This shift is leading to greater healthcare expenditure and increasing demand for advanced therapeutics for older patients, increasing the demand for market dominance.
   

Based on end use, the global acute coronary syndrome therapeutics market is divided into hospitals, cardiology clinics, ambulatory surgical centers and other end users. The hospital pharmacies segment dominated the market in 2024 and is expected to reach USD 8 billion till 2034.
 

• Hospitals are the primary option due to their central role in emergency care, diagnosis, and cardiovascular treatment. Acute coronary syndrome is a medical emergency that requires rapid diagnosis and treatment through advanced procedures that are only available in hospitals. Due to this, hospitals are the primary point of care for patients.
   
• Additionally, hospitals have cardiovascular clinical trials and post-acute cardiac rehabilitation programs, providing continuity of care with medication therapy, lifestyle management, and prevention. This care includes both treatment and recovery centers, making them the largest segment in the market.
   
• Hospitals are the first point of access during emergency situations, especially in urban centers. Public and private investments into hospital infrastructure, in emerging markets such as India, China, and Brazil, have further increased accessibility and affordability of treatments, expanding hospital-based therapeutics.

The North America acute coronary syndrome therapeutics market dominated the global market with a market share of 42.1% in 2024. The market is stimulated by the rising prevalence of cardiovascular diseases and increased expenditure on advanced cardiac care and preventive therapeutics. Advancements in pharmacological treatment options and a growing emphasis on early diagnosis and evidence-based clinical guidelines further support market expansion in the region.
 

The U.S. acute coronary syndrome therapeutics market was valued at USD 3.1 billion and USD 3.2 billion in 2021 and 2022, respectively. The market size reached USD 3.6 billion in 2024, growing from USD 3.4 billion in 2023.
 

• The higher number of acute coronary syndrome cases in the U.S. is stimulating demand for effective therapeutic solutions. According to the American College of Cardiology, about 1.2 million people in the U.S. get hospitalized due to acute coronary syndrome each year, with STEMI contributing 30% of the cases.
   
• Additionally, U.S. Cardiology Review mentions approximately 5 million people go to the emergency department due to chest pain. This growing number of cases has made people aware about the prioritization of short and long-term prevention, with healthcare systems trying and developing solutions to reduce recurrent events and improve patient compliance.
   
• The increasing public health awareness campaigns for lifestyle-related risk factors such as obesity, diabetes and hypertension, along with developing healthcare infrastructure and government cardiovascular programs, further stimulate the market.
   
• The U.S. has implemented widespread use of guideline-directed medical therapy, which includes both inpatient and outpatient care settings. As complications remain a major contributor to healthcare expenditures, the use of timely and effective therapies is increasingly used as a cost-effective strategy for improving national health outcomes and reducing cardiac care costs.
   

Europe acute coronary syndrome therapeutics market accounted for USD 2.5 billion in 2024 and is anticipated to show lucrative growth over the forecast period.
 

• Rising awareness and adoption of evidence-based cardiovascular care programs in the region, along with increasing government initiatives to reduce the burden of heart disease, is anticipated to spur growth in the market.
   
• Moreover, advancements in drug technologies, such as novel anticoagulants, high-potency statins, and targeted biologics, along with the introduction of combination therapies and cost-effective generic formulations, boost the requirement for acute coronary syndrome therapeutics in the Europe region.
   
• Also, the presence of key market players in the region strengthens the market. These companies actively participate in innovation through the development of next-generation cardiovascular drugs, expanded treatment access, and partnerships with healthcare systems and public health agencies, thereby advancing market growth.
   

Germany acute coronary syndrome therapeutics market is anticipated to witness considerable growth over the analysis period.
 

• The rising prevalence of cardiovascular diseases and the country's healthcare infrastructure are stimulating growth in the market. The increasing focus on cardiac issue prevention, early diagnosis and standardized and personalized treatment has stimulated demand for effective therapies. According to the German Federal Statistical Office, cardiovascular diseases account for a third, that is 33.3% of all death causes in Germany, with unstable angina contributing to hospital admissions and long-term burdens.
   
• Government initiatives for cardiovascular health and health insurance coverage are prioritizing access to pharmacological treatments, including antiplatelet agents and statins. Germany has clinical integration across hospitals and primary care systems to ensure consistent use of therapy and prevention methods post syndrome. The high investment in care models and preventive methods for cardiology is continuously expanding therapeutic utilization.
   
• Additionally, public health campaigns and partnerships with foundations are increasing awareness for risk factors such as hypertension and cholesterol, further escalating patient adherence and stimulating market growth.
   

The Asia Pacific acute coronary syndrome therapeutics market is anticipated to grow at the highest CAGR of 6.5% during the analysis timeframe.
 

• The market in the Asia Pacific region is growing rapidly due to the rising incidence of acute coronary syndrome cases, increasing public health awareness regarding cardiovascular diseases, and the ongoing improvement of healthcare infrastructure across both urban and rural populations.
   
• Countries such as China, India, and Japan are adopting acute coronary syndrome therapeutics at a faster rate in response to the surge in lifestyle-related risk factors, growing emphasis on preventive cardiology, and government-led initiatives to strengthen emergency cardiac care and early intervention services.
   
• Additionally, the rapid expansion in the number of cardiac care units, specialty hospitals, and primary healthcare centers, combined with national policies aimed at enhancing access to essential cardiovascular medications and integrating acute coronary syndrome treatment protocols into public healthcare systems, is significantly contributing to the accelerated growth of the market across the region.
   

China acute coronary syndrome therapeutics market is predicted to grow significantly over the forecast period.
 

• The high prevalence of diabetes and cardiovascular diseases in China is stimulating the growth of the market. According to NIH, diabetes was a highly prevalent disease among acute coronary syndrome patients in China and over 330 million people in China are affected by cardiovascular diseases, with ischemic heart disease and acute coronary events ranking as the leading causes of mortality.
   
• The growing elderly population, hypertension, along with smoking are further increasing the demand for effective and accessible treatments across the country. According to ResearchGate, more than half of male acute coronary syndrome patients were smokers in China.
   
• The increasing domestic pharmaceutical manufacturing capacity is also stimulating market growth. Chinese pharmaceutical companies such as Tasly Pharmaceutical, CSPC Pharmaceutical Group, and Jiangsu Hengrui Medicine are producing acute coronary syndrome medications. These are contributing to cost-effectiveness in public hospitals and rural clinics, where affordability remains a concerning factor in treatment.
   

Brazil is experiencing significant growth in the Latin America acute coronary syndrome therapeutics market.
 

• Brazil has a high prevalence of cardiovascular diseases. According to the Brazilian Society of Cardiology, ischemic heart disease is a top cause of death in the country. The rising prevalence of factors such as obesity, diabetes and smoking, particularly in urban populations, has increased the demand for effective management.
   
• Limited access to advanced care in remote areas further stimulates the need for pharmacological therapies for treatment.
   
• Additionally, partnerships with international pharmaceutical companies have increased access to a broader range of solutions, improving protection and coverage of diverse population groups.
   
• Lastly, the increasing need for cost-effective and preventive healthcare solutions further drives growth of the market. Government-led awareness campaigns stimulate middle- and low-income communities that enhance accessibility and reduce prevention costs.
   

Saudi Arabia acute coronary syndrome therapeutics market is poised to witness substantial growth in Middle East and Africa market during the forecast period.
 

• The growing number of public health clinics, enhanced treatment accessibility and rising government expenditures on healthcare infrastructure have spurred market development in Saudi Arabia. The country is emphasizing AI-driven healthcare monitoring systems and rapid treatment programs to control mortality rates and reduce long-term care costs.
   
• Saudi Arabia's high prevalence of diseases further stimulates demand for innovative treatment that is aligned with the goals of Vision 2030. The government is investing heavily in disease prevention and public health to expand awareness and reduce the burden of diseases through long-term control programs.
   

Acute Coronary Syndrome Therapeutics Market Share

Competition in the acute coronary syndrome therapeutics industry is marked by well-established companies, emerging firms and local players fighting to capture a larger share of the market. The top 5 players such as Merck, Pfizer, Eli Lilly, Novartis and Bristol Myers Squibb account for approximately 65% of the global market. These key players focus on various strategies such as acquisitions, business expansion and novel product launches to consolidate their market presence. Additionally, there are several local and regional players operating in the market, boosting competition by providing affordable options at lower costs. These players are also involved in several strategies such as mergers, acquisitions, and novel product launches to expand their product offerings.
 

Acute Coronary Syndrome Therapeutics Market Companies

Few prominent players operating in the acute coronary syndrome therapeutics industry includes:

• AstraZeneca
• Azurity Pharmaceuticals
• Baxter Healthcare
• Boehringer Ingelheim
• Bristol Myers Squibb
• Cipla
• Eli Lilly
• Genentech (Roche)
• Intas Pharmaceuticals
• Janssen Pharmaceuticals
• Merck
• Novartis
• Pfizer
• Ranbaxy Laboratories
• Sanofi
   
• AstraZeneca is a leader in cardiovascular therapeutics with its drug named Brilinta, an antiplatelet agent widely used for managing acute coronary syndrome patients. The drug is approved in markets including the U.S., Europe and Asia-Pacific and is safe and effective in reducing cardiovascular issues. The company's strong research and development pipeline and global manufacturing capabilities support availability in hospital and outpatient settings.
   
• Merck is a key player in the acute coronary syndrome therapeutics market due to innovative anticoagulant and cholesterol-lowering therapies that target risk factors in acute coronary events. The company's portfolio includes oral anticoagulants and PCSK9 inhibitors, approved across major markets. Merck has large-scale manufacturing capabilities and strong collaborations with healthcare systems to ensure accessibility and integration of therapies into standard management worldwide.
   

Acute Coronary Syndrome Therapeutics Market Industry News

• In April 2024, Biome launched an acute coronary syndrome module to help healthcare systems improve management of chest pain care and operational efficiency. The module provides near real-time monitoring of clinical outcomes for hospitals pursuing chest pain center certification. It enhances patient care in emergency and hospital settings.
   
• In June 2023, the U.S. FDA approved LODOCO, the first anti-inflammatory drug to reduce cardiac events including myocardial infarction and stroke in patients, lowering cardiovascular risk by 31%. This was a new approach targeting inflammation alongside cholesterol in acute coronary syndrome management.
   
• In May 2023, Milvexian received FDA fast track designation for all indications in the Phase 3 Librexia program, including ischemic stroke, acute coronary syndrome and atrial fibrillation. The program aims to reduce thrombotic events with less bleeding risk.
   

The acute coronary syndrome therapeutics market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 - 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Type

• Non-ST-elevation myocardial infarction (NSTEMI)
• ST-elevation MI (STEMI)
• Unstable angina

Market, By Drug Class

• Antiplatelet therapy
• Anticoagulants
• Beta blockers
• Nitrates
• Thrombolytics
• Other medications

Market, By Route of Administration

• Oral
• Injectables

Market, By Age Group

• Adult
• Geriatric

Market, By End Use

• Hospitals
• Cardiology clinics
• Ambulatory surgical centers
• Other end use

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudia Arabia
  • UAE